Alembic rides generic Abilify wave amid compliance wins

Shares of Alembic Pharmaceuticals surged on Indian bourses, after the US FDA cleared the first set of generic versions of Otsuka's schizophrenia and bipolar disorder drug Abilify (aripiprazole).

More from Neurological

More from Therapy Areas